Aimmune's PhIII peanut allergy study wows on the primary endpoint, setting up FDA pitch -- and shares slide
Four months after DBV Technologies stock was crushed by a shaky set of pivotal data for its peanut allergy drug, rival Aimmune Therapeutics $AIMT says its Phase III has come through with a promising set of results. And the win sets up an FDA application later this year for the pioneering drug, with a European pitch to follow soon after.
Of the 554 patients in the study, 67.2% of the group in the AR101 drug arm were able to tolerate at least a 600 mg dose of peanut protein, protecting them from a potentially deadly allergic reaction against a small exposure. In the placebo arm, only 4% of the 4- to 17-year-olds in the study could say the same.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.